Enhanced myogenic constriction of mesenteric artery in heart failure relates to decreased smooth muscle cell caveolae numbers and altered AT

European Journal of Heart Failure

Volumn 11, Issue 3, 2009, Pages 246-255

  Xu, Ying ^a,b   Henning, Rob H ^a   Sandovici, Maria ^a   Van Der Want, Johannes J ^a   Van Gilst, Wiek H ^a   Buikema, Hendrik ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

AT; Caveolae; Chronic heart failure; Myogenic constriction

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAVEOLA; HEART FAILURE; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; ANIMAL; CELL COUNT; COMPARATIVE STUDY; DISEASE MODEL; ELECTRON MICROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; HEART CONTRACTION; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; ULTRASTRUCTURE; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; WISTAR RAT;

ANIMALS; CAVEOLAE; CELL COUNT; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE; HEART FAILURE; IMMUNOHISTOCHEMISTRY; MALE; MESENTERIC ARTERIES; MICROSCOPY, ELECTRON; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL CONTRACTION; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASOCONSTRICTION;

EID: 65549131596     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfn027     Document Type: Article

References (30)

1. Schrier RW, Abraham WT. Mechanisms of disease - Hormones and hemodynamics in heart failure. N EngJ Med 1999;341:577-585.
2. Davis MJ, Hill MA. Signaling mechanisms underlying the vascular myogenic response. Physiol Rev 1999;79:387-423.
3. Gschwend S, Henning RH, Pinto YM, de Zeeuw D, van Gilst WH, Buikema H. Myogenic constriction is increased in mesenteric resistance arteries from rats with chronic heart failure: instantaneous counteraction by acute AT(1) receptor blockade. Br J Pharmacol 2003;139:1317-1325.
4. Kagiyama S, Eguchi S, Frank GD, Inagami T, Zhang YC, Phillips MI. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation 2002;106: 909-912.
5. Ushio-Fukai M, Hilenski L, Santanam N, Becker PL, Ma Y, Griendling KK, Alexander RW. Cholesterol depletion inhibits epidermal growth factor receptor transactivation by angiotensin II in vascular smooth muscle cells: role of cholesterol-rich microdomains and focal adhesions in angiotensin II signaling. J Biol Chem 2001;276:48269-48275.
6. Shah BH. Epidermal growth factor receptor transactivation in angiotensin II-induced signaling: role of cholesterol-rich microdomains. Trends Endocrinol Metab 2002;13:1 -2.
7. Fielding CJ. Caveolae and signaling. Curr Opin Lipidol 2001;12:281-287.
8. Darblade B, Caillaud D, Poirot M, Fouque M, ThiersJC, Rami J, Bayard F, ArnalJF. Alteration of plasmalemmal caveolae mimics endothelial dysfunction observed in atheromatous rabbit aorta. Cardiovasc Res 2001;50:566-576.
9. Ratajczak P, Damy T, Heymes C, Oliviero P, Marotte F, Robidel E, Sercombe R, Boczkowski J, Rappaport L, Samuel JL Caveolin-1 and -3 dissociations from caveolae to cytosol in the heart during aging and after myocardial infarction in rat. Cardiovasc Res 2003;57:358-369.
10. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC, Schedl A, Haller H, Kurzchalia TV. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001;293:2449-2452.
11. Dreja K, Voldstedlund M, Vinten J, Tranum-Jensen J, Hellstrand P, Sward K. Cholesterol depletion disrupts caveolae and differentially impairs agonist-induced arterial contraction. Arterioscler Thromb Vasc Biol 2002;22:1267-1272.
12. Sun RJ, Muller S, Zhuang FY, Stoltz JF, Wang X. Caveolin-1 redistribution in human endothelial cells induced by laminar flow and cytokine. Biorheology 2003; 40:31-39.
13. Ballard-Croft C, Locklar AC, Kristo G, Lasley RD. Regional myocardial ischemia-induced activation of MAPKs is associated with subcellular redistribution of caveolin and cholesterol. Am J Physiol Heart Circ Physiol 2006;291: H658-H667.
14. Ushio-Fukai M, Zuo L, Ikeda S, Tojo T, Patrushev NA, Alexander RW. cAbl tyro-sine kinase mediates reactive oxygen species- and caveolin-dependent AT1 receptor signaling in vascular smooth muscle: role in vascular hypertrophy. Circ Res 2005;97:829-836.
15. Suzuki H, Motley ED, Frank GD, Utsunomiya H, Eguchi S. Recent progress in signal transduction research of the angiotensin II type-1 receptor: protein kinases, vascular dysfunction and structural requirement. Curr Med Chem Cardiovasc Hematol Agents 2005;3:305-322.
16. Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S. Angiotensin II signal transduction through the AT(I) receptor: novel insights into mechanisms and pathophysiology. Clin Sci 2007;112:417-428.
17. Ohtsu H, Dempsey PJ, Frank GD, Brailoiu E, Higuchi S, Suzuki H, Nakashima H, Eguchi K, Eguchi S. ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. Arterioscler Thromb Vasc Biol 2006;26:E133-E137.
18. Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T. Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem 2001;276:7957-7962.
19. Wyse BD, Prior IA, Qian HW, Morrow IC, Nixon S, Muncke C, Kurzchalia TV, Thomas WG, Parton RG, Hancock JF. Caveolin interacts with the angiotensin II type 1 receptor during exocytic transport but not at the plasma membrane. J Biol Chem 2003;278:23738-23746.
20. Ishizaka N, Griendling KK, Lassegue B, Alexander RW. Angiotensin II type 1 receptor - Relationship with caveolae and caveolin after initial agonist stimulation. Hypertension 1998;32:459-466.
21. Gaborik Z, Szaszak M, Szidonya L, Balla B, Paku S, Catt KJ, Clark AJL, Hunyady L. beta-arrestin- and dynamin-dependent endocytosis of the AT(1) angiotensin receptor. Mol Pharmacol 2001;59:239-247.
22. Smart EJ, Ying YS, Mineo C, Anderson RGW. A detergent-free method for purifying caveolae membrane from tissue-culture cells. Proc Natl Acad Sci USA 1995; 92:10104-10108.
23. Lambert S, Vind-Kezunovic D, Karvinen S, Gniadecki R. Ligand-independent activation of the EGFR by lipid raft disruption. J Invest Dermatol 2006;126:954-962.
24. Westover EJ, Covey DF, Brockman HL, Brown RE, Pike LJ. Cholesterol depletion results in site-specific increases in epidermal growth factor receptor phosphoryl-ation due to membrane level effects. Studies with cholesterol enantiomers. J Biol Chem 2003;278:51125-51133.
25. Pike LJ, Casey L Cholesterol levels modulate EGF receptor-mediated signaling by altering receptor function and trafficking. Biochemistry 2002;41:10315-10322.
26. Sun Y, Weber KT. Angiotensin-II receptor-binding following myocardial-infarction in the rat. Cardiovasc Res 1994;28:1623 -1628.
27. Yoshimura R, Sato T, Kawada T, Shishido T, Inagaki M, Miyano H, Nakahara T, Miyashita H, Takaki H, Tatewaki T, Yanagiya Y, Sugimachi M, Sunagawa K. Increased brain angiotensin receptor in rats with chronic high-output heart failure. J Card Fail 2000;6:66-72.
28. Mento PF, Pica ME, Hilepo J, Chang J, Hirsch L, Wilkes BM. Increased expression of glomerular AT1 receptors in rats with myocardial infarction. Am J Physiol 1998; 275:H1247-H1253.
29. Jasmin JF, Mercier I, DupuisJ, Tanowitz HB, Lisanti MP. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation 2006;114:912-920.
30. Young LH, Ikeda Y, Lefer AM. Caveolin-1 peptide exerts cardioprotective effects in myocardial ischemia-reperfusion via nitric oxide mechanism. Am J Physiol Heart Circ Physiol 2001;280:H2489-H2495.